Caribou Biosciences Dirección

Dirección controles de criterios 2/4

El CEO de Caribou Biosciences' es Rachel Haurwitz , nombrado en Oct 2011, tiene una permanencia de 12.5 años. compensación anual total es $833.47K, compuesta por 61.6% salario y 38.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.044% de las acciones de la empresa, por valor de $150.40K. La antigüedad media del equipo directivo y de la junta directiva es de 2.4 años y 2.9 años, respectivamente.

Información clave

Rachel Haurwitz

Chief Executive Officer (CEO)

US$3.1m

Compensación total

Porcentaje del salario del CEO	20.0%
Permanencia del CEO	12.6yrs
Participación del CEO	0.04%
Permanencia media de la dirección	2.5yrs
Promedio de permanencia en la Junta Directiva	3yrs

Actualizaciones recientes de la dirección

Recent updates

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

Apr 18

More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%

Apr 17

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up

Feb 15

Caribou Biosciences: Under The Radar With Catalysts Approaching

Feb 01

Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Jan 10

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues

Nov 18

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Feb 24

Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability

Oct 12

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Sep 16

Caribou Biosciences: Potential To Change CAR-T Landscape

Aug 01

Crispred CAR-T Cells In The Clinic

May 19

Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 13

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Rachel Haurwitz en comparación con los beneficios de Caribou Biosciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$115m
Dec 31 2023	US$3m	US$623k	-US$102m
Sep 30 2023	n/a	n/a	-US$95m
Jun 30 2023	n/a	n/a	-US$111m
Mar 31 2023	n/a	n/a	-US$108m
Dec 31 2022	US$833k	US$513k	-US$99m
Sep 30 2022	n/a	n/a	-US$91m
Jun 30 2022	n/a	n/a	-US$85m
Mar 31 2022	n/a	n/a	-US$73m
Dec 31 2021	US$6m	US$527k	-US$67m
Sep 30 2021	n/a	n/a	-US$63m
Jun 30 2021	n/a	n/a	-US$50m
Mar 31 2021	n/a	n/a	-US$38m
Dec 31 2020	US$664k	US$450k	-US$34m
Dec 31 2019	US$540k	US$425k	-US$23m

Compensación vs. Mercado: La compensación total de Rachel($USD3.12M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.52M).

Compensación vs. Ingresos: La compensación de Rachel ha aumentado mientras la empresa no es rentable.

CEO

Rachel Haurwitz (37 yo)

12.6yrs

Permanencia

US$3,116,547

Compensación

Dr. Rachel E. Haurwitz, Ph D., has been the President and Chief Executive Officer at Caribou Biosciences, Inc. since October 2011. She serves as independent Director at Seer, Inc. since December 21, 2023....

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Rachel Haurwitz	Co-Founder	12.6yrs	US$3.12m	0.044% $ 118.8k
Steven Kanner	Chief Scientific Officer	6.9yrs	US$1.22m	0.39% $ 1.1m
Barbara McClung	Chief Legal Officer & Corporate Secretary	9.1yrs	US$1.22m	0.42% $ 1.1m
Jason O'Byrne	CFO & Principal Accounting Officer	3.3yrs	US$3.45m	0.029% $ 77.9k
Daniel Poon	Vice President of Operations & Information Technology	1.9yrs	sin datos	sin datos
Timothy Kelly	Chief Technology Officer	less than a year	sin datos	sin datos
Amy Figueroa	Vice President of Investor Relations & Corporate Communications	2.5yrs	sin datos	sin datos
Reigin Zawadzki	Chief People Officer	less than a year	sin datos	sin datos
Ruhi Khan	Chief Business Officer	2.5yrs	US$1.04m	0% $ 0
Ryan Fischesser	Vice President of Finance & Controller	no data	sin datos	0.12% $ 330.3k

2.5yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CRBU se considera experimentado (2.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Rachel Haurwitz	Co-Founder	12.6yrs	US$3.12m	0.044% $ 118.8k
Andrew Guggenhime	Independent Chairman	3.1yrs	US$202.74k	0% $ 0
Jennifer Doudna	Member of Scientific Advisory Board	no data	sin datos	sin datos
Scott Braunstein	Independent Director	2.9yrs	US$155.86k	0% $ 0
Katy Rezvani	Member of Scientific Advisory Board	no data	sin datos	sin datos
Martin Jinek	Member of Scientific Advisory Board	no data	sin datos	sin datos
Natalie Sacks	Independent Director	6yrs	US$136.99k	0% $ 0
Cameron Turtle	Member of Scientific Advisory Board	no data	sin datos	sin datos
Ran Zheng	Independent Director	2.7yrs	US$157.20k	0% $ 0
Nancy Whiting	Independent Director	2.8yrs	US$140.62k	0% $ 0
Noopur Raje	Member of Scientific Advisory Board	no data	sin datos	sin datos
Ami Bhatt	Member of Scientific Advisory Board	no data	sin datos	sin datos

3.0yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de CRBU se considera experimentada (3 años de antigüedad promedio).

Caribou Biosciences Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Caribou Biosciences, Inc., Annual General Meeting, Jun 13, 2024

Chief Scientific Officer exercised options to buy US$212k worth of stock.

Caribou Biosciences, Inc. Appoints Tim Kelly as Chief Technology Officer

Syed Rizvi to Leave the Caribou Biosciences, Inc. as Chief Medical Officer, Effective from December 31, 2023

Caribou Biosciences, Inc. Appoints Sundar Jagannath to its Scientific Advisory Board

Caribou Biosciences, Inc. Appoints Reigin Zawadzki as Chief People Officer

Recent updates

First quarter 2024 earnings: EPS misses analyst expectations

Caribou Biosciences, Inc., Annual General Meeting, Jun 13, 2024

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%

Caribou Biosciences, Inc. Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

Price target decreased by 8.0% to US$20.25

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up

Chief Scientific Officer exercised options to buy US$212k worth of stock.

Caribou Biosciences: Under The Radar With Catalysts Approaching

Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Caribou Biosciences, Inc. Appoints Tim Kelly as Chief Technology Officer

Syed Rizvi to Leave the Caribou Biosciences, Inc. as Chief Medical Officer, Effective from December 31, 2023

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues

Consensus revenue estimates increase by 71%

Price target decreased by 7.8% to US$22.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Caribou Biosciences, Inc. Appoints Sundar Jagannath to its Scientific Advisory Board

Caribou Biosciences, Inc. Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Caribou Biosciences, Inc. Appoints Reigin Zawadzki as Chief People Officer

Consensus revenue estimates decrease by 19%, EPS upgraded

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.4% to US$24.86

Price target decreased by 8.6% to US$25.14

Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

New minor risk - Shareholder dilution

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Caribou Biosciences, Inc

Pomerantz Law Firm Announces the Filing of A Class Action Against Caribou Biosciences, Inc

Caribou Biosciences, Inc. Appoints Jason V. O'Byrne as Principal Accounting Officer

Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy

Chief Scientific Officer exercised options to buy US$206k worth of stock.

Caribou Biosciences, Inc. Announces the FDA Granted Regenerative Medicine Advanced Therapy and Fast Track Designations to Cb-010, an Allogeneic Anti-Cd19 Car-T Cell Therapy

Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-Bcma Car-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Caribou Biosciences Presents Case Report on Long-Term Follow Up of First Patient Dosed in Phase 1 Antler Trial At the Lymphoma, Leukemia, & Myeloma Congress 2022

Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability

Vice President of Finance & Controller recently sold US$108k worth of stock

Insider exercised options to buy US$314k worth of stock.

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Chief Scientific Officer exercised options and sold US$369k worth of stock

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Caribou Biosciences: Potential To Change CAR-T Landscape

Caribou Biosciences, Inc. Announces Board Changes

Caribou Biosciences, Inc., Annual General Meeting, Sep 20, 2022

Caribou Biosciences, Inc.(NasdaqGS:CRBU) dropped from Russell 2000 Growth Index

Caribou Biosciences, Inc. Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress

Chief Scientific Officer exercised options to buy US$643k worth of stock.

Crispred CAR-T Cells In The Clinic

Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy

Caribou Biosciences, Inc. Appoints David Johnson to its Board of Directors

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Caribou Biosciences, Inc. Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT)

Caribou Biosciences: Selling Close To Cash Balance

Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 Hybrid Congress

Caribou Biosciences, Inc. Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at American Association for Cancer Research Annual Meeting

Consensus estimates of losses per share improve by 13%

Caribou Biosciences, Inc. to Present Preclinical Data on CB-011, an Immune-Cloaked Allogeneic Anti-BCMA CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting

Chief Financial Officer exercised options to buy US$309k worth of stock.

Third quarter 2021 earnings released: US$0.46 loss per share

Less than half of directors are independent

Less than half of directors are independent

We're Not Very Worried About Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Rate

Caribou Biosciences: Another Gene Editor Hurt By The Allogene Hold